Biology of Blood and Marrow Transplantation
Volume 16, Issue 8 , Pages 1180-1185, August 2010

Prediction of Veno-Occlusive Disease Using Biomarkers of Endothelial Injury

Presented in abstract form at the American Society of Hematology Annual Meeting, San Francisco, California, December 2008 and at the American Society of Blood and Marrow Transplantation Annual Meeting, Tampa, Florida, February 2009.

  • Corey Cutler

      Affiliations

    • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • Corresponding Author InformationCorrespondence and reprint requests: Corey Cutler, MD MPH FRCP(C), Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, D1B13, Boston, MA 02115.
  • ,
  • Haesook T. Kim

      Affiliations

    • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • ,
  • Shaké Ayanian

      Affiliations

    • Laboratory Medicine, Children's Hospital Boston, Boston, Massachusetts
  • ,
  • Gary Bradwin

      Affiliations

    • Laboratory Medicine, Children's Hospital Boston, Boston, Massachusetts
  • ,
  • Carolyn Revta

      Affiliations

    • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • ,
  • Julie Aldridge

      Affiliations

    • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • ,
  • Vincent Ho

      Affiliations

    • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • ,
  • Edwin Alyea

      Affiliations

    • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • ,
  • John Koreth

      Affiliations

    • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • ,
  • Philippe Armand

      Affiliations

    • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • ,
  • Robert Soiffer

      Affiliations

    • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • ,
  • Jerome Ritz

      Affiliations

    • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • ,
  • Paul G. Richardson

      Affiliations

    • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • ,
  • Joseph H. Antin

      Affiliations

    • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

Received 13 November 2009; accepted 17 February 2010. published online 24 February 2010.

Predicting the development of veno-occlusive disease (VOD) of the liver remains challenging. We hypothesized that biomarkers of endothelial injury in myeloablative allogeneic transplantation recipients could predict VOD occurrence. We evaluated 4 biomarkers—von Willebrand Factor (vWF), thrombomodulin, E-selectin, and soluble intercellular adhesion molecule-1 (sICAM-1)—weekly in the peritransplantation period in an attempt to predict VOD. In the patients who received sirolimus, vWF, thrombomodulin, and sICAM-1 levels were significantly elevated in patients with VOD compared with those without VOD on day −1 (P ≤ .035), day +7 (P ≤ .0001), and day +14 (P ≤ .004). E-selectin was predictive on day +7 (P = .007). Levels of vWF ≥1400 IU/mL and thrombomodulin ≥100 ng/mL on day +7 were both 100% sensitive and 100% specific in predicting VOD. These biomarkers were informative when adjusted for other risk factors for VOD in regression analysis. Among patients not receiving sirolimus, biomarkers of endothelial injury were not informative. We conclude that vWF, thrombomodulin, and sICAM-1 elevations before and early after transplantation may be useful in predicting VOD in patients receiving sirolimus.

Key Words: Veno-occlusive disease, Endothelium, Sirolimus

 

 Financial disclosure: See Acknowledgments on page 1184.

PII: S1083-8791(10)00087-X

doi:10.1016/j.bbmt.2010.02.016

Biology of Blood and Marrow Transplantation
Volume 16, Issue 8 , Pages 1180-1185, August 2010